



Office of Technology Transfer and Development
31 Center Drive Room 4A29, MSC2479
Bethesda, MD 20892-2479
Michael Shmilovich, Esq, CLP
shmilovm@mail.nih.gov

November 23, 2018

HealthGAP
Knowledge Ecology International (KEI)
Social Security Works (SSW)
The Young Professionals Chronic Disease Network (YP-CDN)
Allison Love Mardini
Brook K Baker
James Love

IN RE: Prospective Grant of Exclusive Patent License: siRNA therapeutics for insulin resistance and Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NASH/NAFLD) (83 FR 55556) to Ovensa, Inc.

Dear Ms. Baker, Ms. Mardini, Mr. Love, KEI, HealthGAP, SSW and YP-CDN:

Thank you for providing us with your comments regarding the aforementioned Federal Register notice.

Prior to posting notices of a proposed grant of exclusive commercialization licenses, the NIH determines that the criteria set forth in 37 CFR 404.7(a)(1)(ii-iii) have been satisfied and that the company applying is qualified both technically and financially to be granted an exclusive license to the Government's intellectual property in the field specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license. We reviewed your comments pertaining to the market, worldwide incidence rates, applicable federal statutes regulations, and pricing and will take them into consideration.

If your organization requests more documentation, such requests should be filed under the Freedom of Information Act. The webpage for the NIH FOIA Office provides more information on filing requests <http://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office/submitting-foia-requests>.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael Shmilovich", is centered below the word "Sincerely,".

Michael A. Shmilovich, Esq., CLP